Inhibitor Therapeutics, Inc.
Inhibitor Therapeutics, Inc. (INTI): 3 pipeline candidates · ~4 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
3.6 months
D/E -1.72 · 0% dilution
Lead: Phase 2
3 candidates
N/A
N/A
A transparent, data-derived signal for Inhibitor Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$14.7M
Cash
$1.3M
Quarterly Burn
$1.1M
Runway
3.6 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| suba-itraconazole | Preclinical |
| suba-itraconazole bccns | Phase 2 |
| uconn itraconazole analogues | Preclinical |
Frequently asked questions
How many drug candidates are in Inhibitor Therapeutics, Inc.'s pipeline?
Inhibitor Therapeutics, Inc. (INTI) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Inhibitor Therapeutics, Inc.'s lead drug candidate?
Inhibitor Therapeutics, Inc.'s most advanced tracked candidate is suba-itraconazole (Preclinical) for Lung cancer.
What is Inhibitor Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Inhibitor Therapeutics, Inc. has approximately 3.6 months of cash runway.
What is Inhibitor Therapeutics, Inc.'s market capitalization?
Inhibitor Therapeutics, Inc.'s market capitalization is approximately $14.7M.
Who is the CEO of Inhibitor Therapeutics, Inc.?
Dr. Francis E. O'Donnell Jr., M.D. is the chief executive officer of Inhibitor Therapeutics, Inc. (INTI).
Get the full picture on Inhibitor Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.